Key result
Takotsubo syndrome is linked to substantial mortality, with long-term death rates reaching ~5.6% per patient-year.
Why the study?
Takotsubo syndrome carries substantial morbidity and mortality, but an incomplete understanding of its pathogenesis has led to a lack of evidence-based interventions to treat acute episodes, avoid recurrences, and prevent major adverse cardiovascular events.
This review highlights that Takotsubo syndrome is not a benign condition, carrying significant morbidity and mortality, and underscores the urgent need for randomized controlled trials to establish evidence-based treatments.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“It's a very unusual condition and quite unlike anything else”
“It shows the diversity of possible causes and presentations of takotsubo syndrome and gives us a better sense of how people may be affected”
Challenges prior benign view of Takotsubo syndrome; supports urgent randomized trials to establish evidence-based therapies.
Takotsubo syndrome is a condition characterized by acute transient left ventricular systolic dysfunction, which at presentation can be challenging to distinguish from acute myocardial infarction. Although previously thought to be a benign, self-limiting condition, recent studies have confirmed that patients with takotsubo syndrome have persistent subtle ongoing cardiac dysfunction, and many continue to have limiting symptoms despite restoration of left ventricular ejection fraction. Moreover, these patients have a substantial burden of morbidity and mortality, as well, with high rates of subsequent major adverse cardiovascular events that approach those of patients with acute coronary syndrome. The mechanisms behind this condition remain elusive. Despite substantial research, the medical community continues to have an incomplete understanding of its underlying pathogenesis and pathophysiology. Catecholamine-induced myocardial injury is the most established and well-known theory, but this does not explain all the clinical features and presentations of the condition, and numerous other pathways and abnormalities are emerging. Because of the poor understanding of its underlying pathophysiology, there is a lack of evidence-based interventions to treat the acute episode, to avoid recurrences, and to prevent major adverse cardiovascular events. This highlights the need for further research to gain a better understanding of the underlying pathophysiology to inform appropriate randomized controlled trials of interventions targeting the causative pathways. Only then can evidence-based management strategies be established to improve clinical outcomes of this potentially lethal condition.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a review in Takotsubo syndrome. Takotsubo syndrome is associated with substantial morbidity and mortality, including an in-hospital mortality comparable to acute ST-segment elevation myocardial infarction and a long-term all-cause death rate of 5.6% per patient-year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: